Healthy Life Journal

These diseases often come in secret, even without a complaint. But if left, hypertension can lead to cardiovascular disease and other dangerous diseases.

Arrival of a sudden a horrible plus the effect of making health hypertension dubbed “the silent disease”. The average person does not know himself suffered from hypertension before their blood pressure checked. However, many people are not aware or are still reluctant to consult healthcare associated hypertension.

There is a reasonable lazy, but some are not to the doctor because he felt his fine without complaint. Disturbance is also known as heterogeneous group of diseases that can affect anyone from different age groups and socio-economic groups.

Hypertension is a condition when the body loses or unable to control the blood pressure so that excessive pressure. As a result, blood volume increases and narrows blood vessels. Therefore the heart to pump harder to supply oxygen and nutrients to every cell in the body.

The blood pressure measured by pressure against the blood vessel wall (in mmHg). Number 120 / 80 mmHg is normal blood pressure that occurs when the heart pumps (systole) and resting (diastole).

We have suffered hypertension estimated one billion people around the world and a major causative factor of cardiovascular events; number one cause of death worldwide. And is also known that high blood pressure is a major cause of coronary artery disease or coronary artery disease (CAD) and heart failure or heart failure.

Cardiovascular disease (CVD) which is the terminology for the disorders that cause heart disease and blood vessel, said to be the main cause of death and disability worldwide. The comparison is one of the three deaths in the dunia.Terbukti hypertension is a risk factor causing the most morbidity and mortality due to CVD.

Neutralize the pressure by the World valsatran medicine continues to work hard to find a solution to this disease. Last found valsartan therapy to reduce cardiovascular events. Drug efficacy has been announced on 1 September and in the Congress of the European Society of Cardiology (ESC) in Barcelona, Spain.

Antihypertensive drugs are categorized as group angiotensin receptor blockers (ARBs), the non-ARB group can reduce cardiovascular events in hypertensive patients as much as 45 per cent. Research by the Kyoto Heart Study involving 3042 Japanese patients with blood pressure uncontrolled.

They use non-medical type? ARB with one or more cardiovascular risk factors (such as diabetes or obesity, smoking, or history of heart disease).

Kyoto Heart Study is an independent research to see the effect of protection against morbidity and mortality of cardiovascular (CV) of the addition of valsartan compared with conventional treatment (except for groups of ACE-inhibitors [ACEis] or angiotensin receptor blockers [ARBs], etc.) Japanese patients with hypertension (pressure high blood pressure) are not controlled and have a high risk of cardiovascular events.

Prof. Dr. Hiroaki Matsubara of Cardiovascular Medicine at the Kyoto Prefectural University of Medicine, Kyoto, Japan and Main Researcher of Kyoto mention Heart Study, valsartan could significantly reduce the total incidence of complications of hypertension in heart, brain, and vascular patients at high risk of incident Cardiovascular.

“These benefits beyond the benefits of lowering blood pressure (independent of the level of blood pressure reduction). In addition, this study also confirmed the benefits of inhibition of the renin angiotensin system in patients of East Asia,” he said.

Meanwhile, according to the hypertension expert from the National Heart Center Harapan Kita, Dr Santoso Karokaro MPH, SpJP (K) FIHA, based on household health survey in 2004, prevalence of hypertension in Indonesia in people over the age of 35 years more than 15.6 percent.

Even in highly developed countries like the United States, every 2 minutes of death due to hypertension and its complications.

“Therefore, if there is a therapy that can reduce the risk of morbidity and mortality, particularly in Asia, this may provide benefits for patients,” he said during a media gathering to announce the latest findings about hypertension drugs valsartan therapy held Novartis Penang Bistro restaurant, Friday (11/09).

He added that the results of this study reinforce the JIKEI previous Heart Study has been done on Asian patient population.

Therefore, for Indonesia, which is part of Asia, valsartan proved to have benefits for patients at high risk.

“We are delighted that this independent study once again proves why valsartan treatment of hypertension is number one in the world,” said Roger Polman, President Director of PT Novartis Indonesia.

Roger said, the evidence that confirms these results are not found in treatment studies of other similar ARB. This may indicate differences in the ARB class.

“With this evidence, both medical experts and patients may have a basis to continue their treatment with valsartan as the basis of their blood pressure management,” he said.

Professor Gordon T McInnes, Clinical Pharmacology, University Division of Cardiovascular and Medical Sciences, Western Infirmary, Glasgow said the Kyoto Heart Study also included patients with metabolic diseases and obesity, as well as some who have the habit of smoking.

“With these reasons, the results of this study may be relevant not only for patients in Japan, but also for other populations in which cardiovascular risk factor prevalence was very high,” he said